Peppermint Oil

This systematic review and meta-analysis assessed the efficacy of peppermint oil for IBS by pooling 10 randomized controlled trials involving 1030 patients. Peppermint oil was superior to placebo for global IBS symptoms, with an RR of not improving of 0.65 (95% CI 0.43 to 0.98) and a number needed to treat of 4. For abdominal pain specifically, peppermint oil was also superior (RR 0.76, 95% CI 0.62 to 0.93, NNT 7). However, adverse events were more common with peppermint oil than placebo (RR 1.57). The authors graded the overall quality of evidence as very low due to heterogeneity in trial methods, risk of bias, and small sample sizes. Despite these caveats, the direction of benefit was consistent across studies and the effect sizes were clinically meaningful. The authors noted that peppermint oil is one of few interventions for IBS with a favorable therapeutic gain relative to its side-effect profile.

This meta-analysis pooled data from 12 randomized controlled trials with 835 IBS patients to assess the efficacy of peppermint oil versus placebo. Peppermint oil significantly improved global IBS symptoms with a risk ratio of 2.39 (95% CI 1.93 to 2.97), yielding a number needed to treat of 3. For abdominal pain specifically, peppermint oil also showed benefit with a risk ratio of 1.78 (95% CI 1.43 to 2.20, NNT 4). The pooled analysis showed consistent direction of benefit across studies. The authors concluded that peppermint oil is a safe and effective short-term treatment for IBS, though they noted that individual trial quality was often limited by small sample sizes and variable methodology. The favorable NNTs suggest that peppermint oil ranks among the more effective symptomatic interventions for IBS relative to its safety profile.

This rigorous randomized, double-blind, placebo-controlled trial evaluated enteric-coated peppermint oil (180 mg TID) versus placebo in 190 IBS patients over 6 weeks. The primary outcome, change in abdominal pain severity, showed no statistically significant difference between peppermint oil and placebo (p = 0.97). Both groups experienced substantial improvement from baseline, suggesting a large placebo response. Global IBS symptom severity and adequate-relief responder rates were also similar between groups. The trial was well designed with proper randomization, blinding, and Rome IV diagnostic criteria. The authors noted that the large placebo response in both arms may have obscured a treatment effect, and that the findings contrast with earlier meta-analytic results which pooled mostly older and smaller trials. This study is important because it is one of the few modern, adequately powered, well-designed individual RCTs of peppermint oil for IBS, and its null result raises important questions about the robustness of pooled positive findings from older literature.

This pediatric dose-comparison RCT established dose-proportional menthol pharmacokinetics for enteric-coated peppermint oil in children with functional abdominal pain. The higher dose (900 mg) significantly reduced colonic and whole-gut contraction frequency compared to 540 mg, confirming that systemic menthol concentration directly correlates with gut motility suppression. This study provides the first formal PK-pharmacodynamic link for peppermint oil in a pediatric population, reinforcing the antispasmodic mechanism (calcium channel blockade) demonstrated in adult studies.